Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

16.48
-0.7400-4.30%
Post-market: 16.500.0200+0.12%19:31 EST
Volume:3.01M
Turnover:50.02M
Market Cap:1.68B
PE:-3.18
High:17.35
Open:16.94
Low:16.43
Close:17.22
52wk High:39.89
52wk Low:12.73
Shares:101.92M
Float Shares:77.74M
Volume Ratio:0.72
T/O Rate:3.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1758
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.98%
PB:-4.47
PE(LYR):-2.83

Loading ...

Ultragenyx Stock Gets Gene Therapy Review As 2027 Profit Plan Takes Shape

Simply Wall St.
·
Nov 19

Movement Alert|Ultragenyx Pharmaceutical Intraday Rise 5.03% in Regular Trading, London investor meeting and UK review progress support sentiment

Market Focus
·
Nov 19

Ultragenyx Pharmaceutical (RARE) Gains MHRA Momentum, Is A 36% Undervaluation Enough?

Simply Wall St.
·
Nov 18

Ultragenyx price target lowered to $24 from $35 at Guggenheim

TIPRANKS
·
Nov 17

Is Ultragenyx Pharmaceutical (RARE) Fully Priced After The UX111 Review?

Simply Wall St.
·
Nov 15

MHRA Filing Acceptance Could Be A Big Step For Ultragenyx Stock (RARE)

Simply Wall St.
·
Nov 12

Ultragenyx Subsidiary Amlogenyx to Attend Jefferies Healthcare Conference in London

Reuters
·
Nov 12

Ultragenyx Participates in UBS and Jefferies Investor Conferences

Reuters
·
Nov 11

Ultragenyx Pharmaceutical (RARE) Could Be 38% Undervalued After UK UX111 Filing Progress

Simply Wall St.
·
Nov 11

UK MHRA Accepts Ultragenyx Gene Therapy Application for Review

Reuters
·
Nov 06

Ultragenyx Pharmaceutical - Mhra Accepts Ultragenyx Maa for Rebisufligene Etisparvovec (Ux111) on Oct 28, 2026

THOMSON REUTERS
·
Nov 06

Where Does Ultragenyx Pharmaceutical (RARE) Value Sit After Cost Cuts?

Simply Wall St.
·
Nov 06

Eton Pharmaceuticals Q3 Revenue Jumps 158% on Portfolio Sales Growth; Raises 2026 Outlook

Reuters
·
Nov 06

Ultragenyx Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Nov 06

Ultragenyx price target lowered to $22 from $32 at Citi

TIPRANKS
·
Nov 06

ANI Pharmaceuticals Q3 Revenue Beats Estimates on Cortrophin Gel Growth

Reuters
·
Nov 05

Agios Pharma Q3 Product Revenue Surges; Will Have Cut 100+ R&D Jobs in 2026

Reuters
·
Nov 05

Barclays Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Nov 05

Rare Disease Drug Developer Egetis Q3 Revenue Rises on Emcitate Sales

Reuters
·
Nov 05

X4 Pharmaceuticals Q3 Revenue Rises on Xolremdi Sales

Reuters
·
Nov 05